Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23172216 | 1.00 | GAA (0.38) | GAADNM1TLR8TP53LMNA | |
| SCHEMBL20633873 | 0.98 | GAA (0.39) | GAADNM1TLR8TP53LMNA | |
| SCHEMBL20414770 | 0.98 | GAA (0.39) | GAADNM1TLR8TP53LMNA | |
| SCHEMBL19237046 | 0.98 | GAA (0.39) | GAADNM1TLR8TP53LMNA | |
| SCHEMBL19544072 | 0.98 | GAA (0.39) | GAADNM1TLR8TP53LMNA | |
| SCHEMBL22350121 | 0.95 | GAA (0.37) | GAATLR8TP53 | |
| SCHEMBL23219668 | 0.92 | GAA (0.37) | GAATLR8TP53 | |
| SCHEMBL26242383 | 0.83 | LMNA (0.32) | DNM1LMNACA2 | |
| SCHEMBL22597187 | 0.83 | GAA (0.38) | GAATLR8TP53LMNA | |
| SCHEMBL23082899 | 0.83 | GAA (0.38) | GAATLR8TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364082-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364082-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | GAA 2709/4885DNM1 673/4885TLR8 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.